A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Autism Spectrum Disorders

In brief

Background: \- Some children with autism spectrum disorders (ASD) do not have normal sleep cycles. Some of these children spend very little time in the rapid eye movement (REM) stage of sleep. Some studies suggest that less time in REM sleep can be associated with learning and behavior problems. Donepezil is a medication used to treat Alzheimer s disease. Donepezil can increase REM sleep in some adults with different disorders. A small study showed that Donepezil can also increase REM sleep in children with ASD. Researchers now want to see if Donepezil can improve communication skills and social interaction in children with ASD. They also want to see if any change in symptoms seems to come from changes in REM sleep. Objectives: \- To see if a medication, Donepezil, can improve the way communication skills and social interaction develop in young children with autism spectrum disorders. Eligibility: \- Children 22 to 44 months of age with ASD. Design: * Participants will be screened with a blood test, heart tests, and a sleep study. During the sleep study, children will sleep in a darkened room for 2 nights with electrodes on their body and a tube under their nose. Parents can sleep in the room with their child. A technician will monitor the room all night. * Participants will take the study medication once a day. * Treatment will be monitored at visits every 3 months. At each visit the participant will take blood tests, heart tests, or behavior tests. Participants will have 2 more sleep studies. * Participation will end after 18 months.

Key facts

Study ID

NCT01887132

Run by

National Institute of Mental Health (NIMH)

People needed

5

Starts

2013-06-01

Expected to finish

2015-12-01

Last updated by the study team

2017-09-25

Who can join

Age: 2 and older, up to 4. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Serious, unstable illnesses including gastroenterologic, respiratory, cardiovascular endocrinologic, immunologic, or hematologic disease.
• Renal or hepatic dysfunction that would interfere with excretion or metabolism of donepezil as evidenced by increase above upper limits of normal for BUN/creatinine, or two-fold elevation of serum transaminases (ALT/SGPT, AST/SGOT) or gamma glutamate (GGT).
• Documented history of hypersensitivity or intolerance to donepezil or other piperidine derivative.
• Subjects must not be taking any medication known to affect REM sleep (or sleep
• architecture in general) or that is contraindicated for co-administration with donepezil.
• Presence or history of other unstable neurological disorders such as seizure disorders,
• metabolic disorders, narcolepsy or movement disorders.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.